Sirtuins and Metabolism Biomarkers in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: a Correlation Study with Clinical Outcomes and Cognitive Impairments
- PMID: 37995076
- DOI: 10.1007/s12035-023-03778-x
Sirtuins and Metabolism Biomarkers in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: a Correlation Study with Clinical Outcomes and Cognitive Impairments
Abstract
Multiple sclerosis (MS) is a primary inflammatory demyelinating disease with different clinical courses and subtypes. The present study aimed to determine whether mitochondrial dysfunction and sirtuins 1 and 3, as metabolism and epigenetic modifying factors, might contribute to MS disease progression measured by physical disability and cognitive impairment.The volunteers (n = 20 controls, n = 59 MS) were recruited and assessed for cognitive function and disability scores; then, patients were clinically classified as relapsing-remitting (RR) in remission phase, RR in relapse phase, and secondary progressive MS. We measured sirtuin (SIRT) 1 and 3 levels, mitochondrial complex I, IV, aconitase, and α-ketoglutarate dehydrogenase (α-KGD) activity in the peripheral blood mononuclear cells (PBMCs). Furthermore, SIRT1, pyruvate, lactate, and cytochrome c (Cyt c) were determined in plasma. Finally, we performed postmortem tissue immunohistochemistry to assess the level of SIRT1 and SIRT3 in the brain lesions of patients with MS.Increased disability and cognitive impairment in patients were correlated. Plasma level of lactate showed a correlation with the disability in MS patients; moreover, a trend toward increased Cyt c plasma level was observed. Investigation of PBMCs exhibited decreased SIRT1 during the relapse phase along with a reduced complex IV activity in all MS subgroups. α-KGD activity was significantly increased in the RR-remission, and SIRT3 was elevated in RR-relapse group. This elevation correlated with disability and cognitive impairment. Finally, immunohistochemistry demonstrated increased levels of SIRT1 and 3 in the brain active lesion of patients with MS.Our data suggest that mitochondrial dysfunction and alteration in some epigenetics and metabolism modifying factors in the CNS and peripheral blood cells may contribute or correlate with MS progression.
Keywords: Cognitive impairment; Disability; Mitochondrial dysfunction; Multiple sclerosis; Sirtuins.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Changes in mitochondrial function in patients with neuromyelitis optica; correlations with motor and cognitive disabilities.PLoS One. 2020 Mar 26;15(3):e0230691. doi: 10.1371/journal.pone.0230691. eCollection 2020. PLoS One. 2020. PMID: 32214385 Free PMC article.
-
Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing-remitting and secondary progressive multiple sclerosis patients.Clin Neurol Neurosurg. 2001 Dec;103(4):206-11. doi: 10.1016/s0303-8467(01)00144-5. Clin Neurol Neurosurg. 2001. PMID: 11714562
-
Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis.Neurol Neuroimmunol Neuroinflamm. 2021 Apr 27;8(4):e998. doi: 10.1212/NXI.0000000000000998. Print 2021 Jul. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33906937 Free PMC article.
-
Teriflunomide for multiple sclerosis.Cochrane Database Syst Rev. 2016 Mar 22;3(3):CD009882. doi: 10.1002/14651858.CD009882.pub3. Cochrane Database Syst Rev. 2016. PMID: 27003123 Free PMC article. Review.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
References
-
- Kister I, Chamot E, Salter AR et al (2013) Disability in multiple sclerosis: a reference for patients and clinicians. Neurology 80:1018–1024. https://doi.org/10.1212/WNL.0b013e3182872855 - DOI - PubMed - PMC
-
- Orton S-M, Herrera BM, Yee IM et al (2006) Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 5:932–936. https://doi.org/10.1016/S1474-4422(06)70581-6 - DOI - PubMed
-
- McFarland HF, Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8:913–919. https://doi.org/10.1038/ni1507 - DOI - PubMed
-
- Trapp BD, Peterson J, Ransohoff RM et al (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–285. https://doi.org/10.1056/NEJM199801293380502 - DOI - PubMed
-
- Scott LJ (2020) Siponimod: a review in secondary progressive multiple sclerosis. CNS Drugs 34:1191–1200. https://doi.org/10.1007/s40263-020-00771-z - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources